Remote Ischemic Preconditioning Ameliorates Anthracycline-induced Cardiotoxicity and Preserves Mitochondrial Integrity
Carlos Galán‐ArriolaiD, Rocío Villena-GutiérreziD, María Isabel Higuero-Verdejo, Iván Alejandro Díaz-RengifoiD, Gonzalo PizarroiD, Gonzalo Javier López, Antonio de Molina-IrachetaiD, Claudia Pérez‐MartíneziD, Rodrigo Damián GarcíaiD, David González CalleiD, Manuel Lobo, Pedro Luis SancheziD, Eduardo OliveriD, Raúl CórdobaiD, Valentı́n FusteriD, Javier Sánchez‐GonzaleziD, Borja IbáñeziD
Abstract
AimsAnthracycline-induced cardiotoxicity (AIC) is a serious adverse effect in a significant proportion of cancer patients. A central mechanism of AIC is irreversible mitochondrial damage. Despite major efforts, there are currently no effective therapies able to prevent AIC. Methods and ResultsForty Large-White pigs were included. In Study 1, 20 pigs were randomized 1:1 to remote ischemic pre-conditioning (RIPC, 3 cycles of 5 min leg ischemia followed by 5 min reperfusion) or no pretreatment. RIPC was performed immediately before each of five intracoronary doxorubicin injections (0.45 mg/kg) given at weeks 0, 2, 4, 6, and 8. A group of 10 pigs with no exposure to doxorubicin served as healthy controls. Pigs underwent serial cardiac magnetic resonance (CMR) exams at baseline and at weeks 6, 8, 12, and 16. After 16-week CMR, pigs were sacrificed and tissue samples collected. In study 2, 10 new pigs received 3 doxorubicin injections (with/out preceding RIPC) and were sacrificed 2 weeks after the third dose. In Study 1, LVEF remained unchanged in doxorubicin-treated pigs until week 6 (time of the fourth doxorubicin injection). From there on, LVEF progressively declined, but LVEF depression was blunted animals receiving RIPC before doxorubicin (RIPC-Doxo), which had a significantly higher LVEF at week 16 than doxorubicin treated pigs that received no pretreatment (Untreated-Doxo) (41.5{+/-}9.1% vs 32.5{+/-}8.7%, p=0.04). Preserved LVEF was mainly due to conserved contractile function, as evidenced by smaller LVESV, and better regional contractile function. In Study 2, transmission electron microscopy (TEM) after 3 doxorubicin doses showed fragmented mitochondria with severe morphological abnormalities in RIPC+Doxo pigs, together with upregulation of fission proteins and autophagy markers on western blot. At the end of the 16-week Study 1 protocol, TEM revealed overt mitochondrial fragmentation with structural fragmentation in Untreated-Doxo pigs, whereas interstitial fibrosis was significantly less severe in the RIPC+Doxo pigs. ConclusionIn a translatable large animal model of AIC, RIPC applied immediately before each doxorubicin injection resulted in preserved cardiac contractility with significantly higher long-term LVEF and less cardiac fibrosis. RIPC prevented mitochondrial fragmentation and dysregulated autophagy from the early stages of AIC. RIPC is a promising intervention for testing in clinical trials in AIC.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 63
- FWCI
- 5.10
- Field percentile
- top 3%
- Assay
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Impaired active myocardial relaxation is the earliest sign of anthracycline cardiotoxicity and reflects selective injury of the cardiomyocyte surface
Céline Guilbeau‐Frugier, Clément Karsenty, … Céline Galès·bioRxiv·Sep 25, 2026
- AICAR prevents doxorubicin-induced heart failure in rats by ameliorating cardiac atrophy and improving fatty acid oxidation
A. Choksey, B. D. Thackray, … K. N. Timm·bioRxiv·Aug 17, 2022
- DRP1 inhibition confers cardioprotection against doxorubicin while preserving anticancer efficacy
Yali Deng, Sebastian Bass-Stringer, … Shiang Yong Lim·bioRxiv·Feb 17, 2026
- CARP Protects Against Doxorubicin-induced Cardiotoxicity through NRF1-driven Mitochondrial Homeostasis
- EPAC1 Inhibition Protects the Heart from Doxorubicin-Induced Toxicity
M. Mazevet, A. Belhadef, … E. Morel·bioRxiv·Jun 16, 2021
- Protection against doxorubicin-induced cardiotoxicity by ergothioneine
I. K. Cheah, R. M. Y. Tang, … B. Halliwell·bioRxiv·Dec 21, 2022